NDAQ:XAIR - Post Discussion
Post by
Red~One on Aug 23, 2022 3:41pm
phase 1 study
Beyond Air affiliate Beyond Cancer doses patient in phase 1 study of ultra-high concentration nitric oxide therapy Beyond Air ( NASDAQ: XAIR ) unit Beyond Cancer said on Tuesday the first patient had been treated in a Phase 1 study to assess the safety and immune biomarkers of ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors. The company expects initial clinical data from the trial in early 2023. The study will evaluate the maximum tolerated dose, safety and immune biomarkers of UNO injection into solid tumors that are not amenable to or have failed standard treatment. The primary endpoints of the early-stage study are the incidence and characteristics of adverse events, serious adverse events, dose-limiting toxicities, and changes in safety parameters. ( XAIR ) rose ~4% premarket. For further details see: Beyond Air affiliate Beyond Cancer doses patient in phase 1 study of ultra-high concentration nitric oxide therapy Source: SeekingAlpha (Aug 23, 2022 09:12:20 EDT) News by QuoteMedia www.quotemedia.com
Be the first to comment on this post